Jasper Summit Research, LLC
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Westerman, Jan
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Active, not recruiting
3
3433
Europe, Canada, US, RoW
Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.
COPD, COPD Exacerbation
01/26
01/26
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Sherer, Donna
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Kulkarni, Tejaswini
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial

Active, not recruiting
4
70
US
Nintedanib, OFEV, Placebo, Standard of Care
Rohit Aggarwal, MD, Boehringer Ingelheim
Myositis Associated Interstitial Lund Disease (MA-ILD)
07/25
12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

Terminated
2
46
Europe, US, RoW
LTP001, Placebo, Standard of Care (SoC)
Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
08/24
09/24
Murray, Brandi
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Westerman, Jan
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TRITON, NCT04320342 / 2020-002389-16: A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

Active, not recruiting
3
3433
Europe, Canada, US, RoW
Beclomethasone Dipropionate, BDP, Glycopyrronium Bromide, glycopyrrolate, GB, Formoterol Fumarate, FF
Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici S.p.A.
COPD, COPD Exacerbation
01/26
01/26
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Sherer, Donna
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Kulkarni, Tejaswini
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial

Active, not recruiting
4
70
US
Nintedanib, OFEV, Placebo, Standard of Care
Rohit Aggarwal, MD, Boehringer Ingelheim
Myositis Associated Interstitial Lund Disease (MA-ILD)
07/25
12/25
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
ASPIRE, NCT06588686: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Recruiting
2
270
Europe, Canada, US, RoW
Buloxibutid, C21, Placebo
Vicore Pharma AB, Population Services International
Idiopathic Pulmonary Fibrosis (IPF)
02/27
03/27
NCT05497284: To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

Terminated
2
46
Europe, US, RoW
LTP001, Placebo, Standard of Care (SoC)
Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
08/24
09/24
Murray, Brandi
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Active, not recruiting
3
576
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25

Download Options